Long-term multidrug- and rifampicin-resistant tuberculosis treatment outcome by new WHO definitions in Germany. Issue 5 (24th November 2022)

• Record Type: Journal Article
• Authors: Otto-Knapp, Ralf; Häcker, Brit; Krieger, David; Stete, Katarina; Starzacher, Katharina; Maier, Christina; Heyckendorf, Jan; Avsar, Korkut; Suárez, Isabelle; Rybniker, Jan; Bauer, Torsten; Günther, Gunar; Lange, Christoph
• Is Part Of: European respiratory journal. Volume 60:Issue 5(2022)
• Publication Date: 2022-11-24
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.00765-2022
• Languages: English
• ISSNs: 0903-1936

Abstract

Multidrug- and rifampicin-resistant tuberculosis (MDR/RR-TB) are growing threats to the goals of the END TB Strategy [1], causing substantial suffering and overwhelming costs for affected patients and families. Global treatment success for MDR/RR-TB is insufficient at only 59%. Germany has a low tuberculosis incidence (5.0 per 100 000) with 2.7% MDR-TB cases. Although resources are available, treatment success for these patients remains below World Health Organization (WHO) targets, according to national surveillance data [2]. However, long-term treatment outcomes are not systematically captured. Long-term outcomes of MDR/RR-TB with 3-year follow-up show 62% favourable outcomes in Germany. 26% were lost to follow-up or transferred. It was possible to categorise 95% of favourable outcomes as cured using the 2021 WHO outcome definitions. https://bit.ly/3bJnvfR